Shenglin Luan

Title: Innovations of Shenglin Luan in Pharmaceutical Research

Introduction

Shenglin Luan is a notable inventor based in Shenzhen, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative compounds that target cancer treatment. His work focuses on creating effective solutions that enhance the efficacy of existing therapies.

Latest Patents

Shenglin Luan holds a patent for a multi-target tyrosine kinase inhibitor. This invention relates to a compound that exhibits protein kinase inhibitory activity, as demonstrated in formula (I). The compound is metabolized into an active small molecule, td32-4, which effectively inhibits tumor growth in vivo, achieving a notable anti-tumor effect. Compared to td32-4, Luan's compound shows significantly improved solubility and oral bioavailability, demonstrating strong anti-tumor activity in animal experiments. The patent also details a synthetic method for the compound and its applications in the pharmaceutical field.

Career Highlights

Shenglin Luan is associated with the Shenzhen Neptunus Pharmaceutical Research Institute Co., Ltd. His work at this institute has allowed him to focus on groundbreaking research that aims to improve cancer treatment options. His dedication to innovation in pharmaceuticals has positioned him as a key figure in the industry.

Collaborations

Shenglin collaborates with talented coworkers, including Lin Yu and Hanlin Feng. Their combined expertise contributes to the advancement of research and development in the pharmaceutical sector.

Conclusion

Shenglin Luan's contributions to pharmaceutical research, particularly through his innovative patent for a multi-target tyrosine kinase inhibitor, highlight his commitment to improving cancer therapies. His work continues to inspire advancements in the field, showcasing the importance of innovation in medicine.